Class summary at a glance.

Every drug in the Serotonin-1b and Serotonin-1d Receptor Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $134.5Mcombined across class
Total Rx claims: 4.2M1.3M unique beneficiaries
Generic mfrs (active): 45across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Sumatriptan

Brand: IMITREX · 2.9M Part D claims (CY24) · 876K beneficiaries · First FDA approval: 1997-01-23

21 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.258

→

Avg plan cost$43.61

Part D spend $83.8M 169× spread, current vs floor

Class share

62%

of class CY24 spend

View profile →

Rizatriptan

Brand: MAXALT · 1.1M Part D claims (CY24) · 356K beneficiaries · First FDA approval: 2012-06-25

7 generic mfrs 0 plans require PA

Low NADAC$0.484

→

Avg plan cost$2.30

Part D spend $26.3M 5× spread, current vs floor

Class share

20%

of class CY24 spend

View profile →

Eletriptan Hydrobromide

Brand: Relpax · 104K Part D claims (CY24) · 31K beneficiaries · First FDA approval: 2002-12-26

7 generic mfrs 0 plans require PA

Low NADAC$1.87

→

Avg plan cost$25.53

Part D spend $13.0M 14× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

Zolmitriptan

Brand: ZOMIG · 79K Part D claims (CY24) · 25K beneficiaries · First FDA approval: 2013-05-14

10 generic mfrs 2 plans require PA

Low NADAC$1.05

→

Avg plan cost$10.50

Part D spend $11.4M 10× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.